<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02622672</url>
  </required_header>
  <id_info>
    <org_study_id>CS2-15095</org_study_id>
    <nct_id>NCT02622672</nct_id>
  </id_info>
  <brief_title>Water-soluble Ubiquinol Supplementation on Blood Glucose, Lipids, Oxidative Stress, and Inflammation in Diabetes</brief_title>
  <official_title>Water-soluble Ubiquinol (a Reduced Form of Coenzyme Q10) Supplementation on Blood Glucose, Lipids, Oxidative Stress, and Inflammation in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yeh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chung Shan Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetes is considered an oxidative stress and a chronic inflammatory disease. Coenzyme Q10
      (ubiquinone) is recognized as a lipid soluble antioxidant. Ubiquinol is a reduced form of
      coenzyme Q10 in our body after food or supplements intakes. Studies have indicated that the
      water-soluble ubiquinol had better antioxidant activity and absorption than lipid-soluble.
      The purpose of this study was to investigate the effects of a water-soluble ubiquinol
      supplement (100 mg/d) on antioxidation and anti-inflammation in diabetes patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with type 2 diabetes will recruit as subjects (n = 50) and randomly assign to
      the placebo (n = 25) or coenzyme Q10 groups (n = 25). The intervention will administer for 12
      weeks. The concentrations of coenzyme Q10, oxidative stress marker (malondialdehyde),
      antioxidant enzymes activities (superoxide dismutase, catalase, and glutathione peroxidase),
      inflammatory markers [C-reactive protein (CRP), and interleukin-6 (IL-6)], and biochemical
      parameters (fasting glucose, A1C, insulin, C-peptide, and lipid profiles), and blood pressure
      will measure. Hopefully, the results of this study could provide the information of
      water-soluble ubiquinol supplement for clinical doctors and dietitians recommend that
      diabetes patients deserve to know whether the use of coenzyme Q10 supplement.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 4, 2016</start_date>
  <completion_date type="Actual">March 1, 2017</completion_date>
  <primary_completion_date type="Actual">October 25, 2016</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting glucose</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of fasting glucose in mmol/L.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Low density lipoprotein-cholesterol (LDL-C)</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of LDL-C in mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high density lipoprotein-cholesterol (HDL-C)</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of HDL-C in mmol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>malondialdehyde (MDA)</measure>
    <time_frame>12 weeks</time_frame>
    <description>plasma level of MDA in micromol/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>catalase (CAT)</measure>
    <time_frame>12 weeks</time_frame>
    <description>red blood cells level of CAT in Units/mg protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>superoxide dismutase (SOD)</measure>
    <time_frame>12 weeks</time_frame>
    <description>red blood cells level of SOD in Units/mg protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>glutathione peroxidase (GPx)</measure>
    <time_frame>12 weeks</time_frame>
    <description>red blood cells level of GPx in Units/mg protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high sensitivity C-reactive protein (hs-CRP)</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of hs-CRP in mg/L.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>high sensitivity interleukin (hs-IL-6)</measure>
    <time_frame>12 weeks</time_frame>
    <description>serum level of hs-IL-6 in pg/mL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glycerin.soy-lecithin, and water</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>water-soluble Ubiquinol 100 mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>water-soluble ubiquinol</intervention_name>
    <description>100 mg/d</description>
    <arm_group_label>Supplement</arm_group_label>
    <other_name>water-soluble coenzyme Q10</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>glycerin.soy-lecithin, and water</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnostic criteria for type 2 diabetes were defined as a glycohemoglobin (A1C) ≧
             6.5%, a fasting glucose ≧ 7.0 mmol/L or a 2-h plasma glucose ≧ 200 mmol/L during an
             oral glucose tolerance test (OGTT), as well as the use of anti-hyperglycemic drugs.

        Exclusion Criteria:

          -  pregnant or lactation women.

          -  patients with liver or renal disease

          -  Antioxidant dietary supplements user.

          -  patients under warfarin therapy.

          -  patients with hypoglycemia (fasting glucose &lt; 60 mg/dL) or hyperlipidemia (fasting
             triglyceride ≧ 500 mg/dL)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping-Ting Lin, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Nutrition, Chung Shan Medical University</affiliation>
  </overall_official>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>December 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2015</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Chung Shan Medical University</investigator_affiliation>
    <investigator_full_name>Yeh</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Antioxidation</keyword>
  <keyword>Anti-inflammation</keyword>
  <keyword>Blood glucose</keyword>
  <keyword>Blood lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

